- Release Date: 27/01/21 08:59
- Summary: Phase II study for eftilagimod alpha in COVID-19 advances
- Price Sensitive: Yes
- Download Document 253.86KB
Ann: Phase II study for eftilagimod alpha in COVID-19 advances
-
- There are more pages in this discussion • 127 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.8¢ |
Change
-0.098(22.4%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 40.0¢ | 23.0¢ | $13.11M | 40.88M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 223317 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 203065 | 12 |
View Market Depth
| Last trade - 14.48pm 27/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |